Merck KGaA

Merck KGaA, commonly branded as Merck, is a German science and technology company headquartered in Darmstadt. Its activities span three principal sectors: Healthcare, Life Science and Electronics. The group develops prescription medicines and therapies, supplies laboratory and biopharmaceutical manufacturing technologies, and produces advanced materials used in displays, semiconductor fabrication and other high-technology applications. The company traces its origins to the Engel pharmacy in Darmstadt, acquired by Friedrich Jacob Merck in 1668. In the nineteenth century, Emanuel Merck transformed the pharmacy into an industrial chemical and pharmaceutical operation. He isolated and manufactured alkaloids and other active substances in standardized quantities, helping establish the business as a supplier to pharmacies and medical manufacturers. Merck was an early commercial producer of morphine and cocaine, although these historical activities belong to a very different regulatory and medical era. Merck’s history is closely connected with the wider Merck family and with the similarly named American company now known as Merck & Co. The American business began as a Merck subsidiary in 1891 but became independent after its confiscation during the First World War. Merck KGaA retains the Merck trademark in most countries, while its North American businesses generally use EMD, EMD Serono, MilliporeSigma and EMD Electronics branding. The distinction has led to recurring trademark disputes and public confusion. For much of its history Merck was privately held by the Merck family. It became a publicly traded German partnership limited by shares in 1995, while the family retained control through E. Merck KG. The company expanded substantially during the 2000s and 2010s through acquisitions, particularly in biotechnology, laboratory science, electronic materials and bioprocessing. Purchases of Serono, Millipore, Sigma-Aldrich, AZ Electronic Materials, Versum Materials and other businesses broadened Merck from a traditional chemicals and pharmaceuticals company into a diversified technology group. Healthcare includes innovative medicines, fertility treatments, endocrinology, neurology and immuno-oncology. Life Science provides laboratory reagents, analytical products, filtration systems, process equipment and raw materials used in research, diagnostics and the manufacture of biologic medicines. Electronics supplies liquid-crystal and other display materials, semiconductor process chemicals, delivery systems and advanced materials. Merck serves customers ranging from hospitals and universities to pharmaceutical manufacturers, chipmakers and consumer-electronics companies. The group operates internationally through hundreds of subsidiaries and uses different commercial names where trademark rights require them. Its long-term positioning combines scientific research with industrial-scale production, with a particular emphasis on specialized, highly regulated or technically demanding markets rather than mass-market consumer products. In recent years it has increased its focus on oncology, immunology, neurology, biopharmaceutical production, mRNA-related capabilities and semiconductor materials while divesting or reshaping selected non-core activities.

Merck KGaA's history begins with the Merck family's pharmacy in Darmstadt, established in 1668. The business gradually moved beyond retail pharmacy into chemical and pharmaceutical production, building an industrial base around active ingredients, specialty chemicals, and laboratory-related products. Its long history is central to the group's corporate identity, although the present-day company is the result of extensive modernization, internationalization, portfolio restructuring, and acquisitions. During the nineteenth and twentieth centuries, Merck developed as a research-oriented chemical and pharmaceutical enterprise. Its activities expanded into medicines, laboratory chemicals, and industrial technologies. International operations and licensing arrangements became increasingly important, while the business developed specialized expertise in pharmaceutical research and chemical manufacturing. The company ultimately adopted the corporate form Merck KGaA, with E. Merck KG serving as the family's general partner and a publicly traded limited partnership structure providing outside investment. In the modern period, Merck organized its activities into healthcare, life science, and performance materials, with the latter later evolving into the Electronics business. Healthcare has focused on specialty pharmaceuticals, including neurology, fertility, immunology, and oncology-related areas. The Life Science business was significantly enlarged by the acquisition of Sigma-Aldrich, which created a broad supplier of laboratory products, research reagents, and biopharmaceutical manufacturing materials. Electronics has developed materials and solutions for display technologies and semiconductor fabrication, giving the group exposure to industrial technology markets in addition to healthcare. The company has also pursued targeted acquisitions to strengthen technology platforms and pharmaceutical pipelines. Purchases and investments in businesses such as Versum Materials and Intermolecular expanded its semiconductor-materials capabilities. In healthcare, acquisitions and partnerships have been used to add late-stage candidates, specialist medicines, and therapeutic technologies. The SpringWorks transaction further emphasized rare tumors and specialty oncology, while the proposed Bio-Techne transaction was presented as a way to deepen Merck KGaA's position in fast-growing life-science markets. Merck's brand architecture requires careful geographic interpretation. Merck KGaA uses the Merck name in much of the world but operates as EMD in the United States and Canada in several contexts. Merck & Co., Inc. is a separate American company that uses Merck in the United States and Canada and MSD in many other countries. Confusion between the two organizations has affected media reports, search results, and commercial descriptions. This dossier therefore limits the selected subject to the Darmstadt-based Merck KGaA and excludes products, executives, and transactions clearly belonging to Merck & Co.

1. 2026Bio-Techne acquisition agreement

   Merck KGaA agreed to acquire Bio-Techne to strengthen its life-science tools, multi-omics, analytics, and bioprocessing offerings.

   Source
2. 2025SpringWorks acquisition completed

   Merck completed the acquisition of SpringWorks Therapeutics, adding medicines for rare tumors and related specialty-care opportunities.

   Source
3. 2019Versum Materials acquisition announced

   Merck expanded its electronics and semiconductor-materials activities through the acquisition of Versum Materials.
4. 2015Sigma-Aldrich acquisition completed

   Merck completed the acquisition of Sigma-Aldrich, substantially expanding its laboratory, research, and bioprocessing portfolio.
5. 1668Merck family pharmacy established

   The Merck family pharmacy in Darmstadt, associated with Friedrich Jacob Merck, became the historical origin of the company.

A science-led, globally diversified company combining healthcare, life-science tools and services, and electronics materials.

• MavencladPrescription medicine

  Mavenclad is an oral multiple-sclerosis medicine marketed by Merck KGaA's healthcare organization. The product is associated with a treatment schedule designed around defined courses rather than continuous daily dosing, making its dosing pattern a central part of its patient and healthcare-professional communication. In the United States and Canada, Merck KGaA's pharmaceutical activities are commonly associated with EMD Serono.

• Sigma-Aldrich portfolioLife-science tools

  The Sigma-Aldrich portfolio includes laboratory reagents, chemicals, analytical products, research materials, and supplies used by academic, pharmaceutical, biotechnology, and industrial laboratories. It forms part of Merck KGaA's broad life-science offering and supports work ranging from basic research to biopharmaceutical development and manufacturing.

• Milli-QLaboratory water purification

  Milli-Q is Merck's laboratory water-purification platform. It is used to produce purified water for analytical, research, and laboratory workflows, with systems and consumables designed for different laboratory requirements and quality levels.

• Electronics materialsSemiconductor and display materials

  Merck's Electronics business supplies materials and related technologies for semiconductor fabrication, displays, and other advanced electronic applications. The portfolio reflects the group's move beyond traditional pharmaceuticals into specialized materials that support manufacturing processes and next-generation device technologies.

• 2026Agreement to acquire Bio-TechneM&A

  Merck KGaA identified life-science tools, multi-omics, analytical technologies, bioprocessing, and advanced therapeutics as growth areas requiring broader capabilities.

  What changed. The company agreed to acquire Bio-Techne in an all-cash transaction, subject to customary conditions and approvals.

  Aftermath. The proposed combination was presented as a means of broadening Merck KGaA's offering across the research and biopharmaceutical value chain; the supplied material does not establish final completion.

  Enterprise value. US$11.3 billion (Transaction announcement, June 2026)

  Source

• 2016United Kingdom trademark ruling involving Merck & Co.Controversy

  The High Court of Justice in the United Kingdom held that Merck & Co. had breached an agreement and infringed Merck KGaA’s rights through use of the Merck name in circumstances directed at the UK market.

  Source
• 2016Trademark dispute with the German Merck GroupControversy

  Merck & Co. and the German Merck Group continued to contest the use of the Merck name in various jurisdictions, reflecting their separate corporate histories and territorial trademark arrangements.

  Source
• 2009Sponsored medical-journal supplementsControversy

  Merck’s Australian affiliate paid Elsevier to produce medical-journal issues that presented reprinted, favorable material without clearly identifying the commercial sponsorship. The practice became public during Vioxx litigation and was acknowledged by an Elsevier executive as unacceptable.

  Source
• 2007Generics UK price and supply-fixing settlementControversy

  Merck’s former British Generics business paid an out-of-court settlement to the UK Department of Health and Social Care concerning allegations that drug companies restricted supplies and increased prices for medicines supplied to the National Health Service.

  Source
• 2004Merck withdraws Vioxx worldwideControversy

  Merck voluntarily removed the COX-2 painkiller Vioxx from worldwide markets after evidence linked prolonged use with increased cardiovascular risk.

  Source
• 2004Vioxx safety controversy and withdrawalControversy

  Merck withdrew Vioxx after clinical evidence indicated increased cardiovascular risks associated with certain patterns of use. The withdrawal generated extensive personal-injury litigation and criticism concerning risk evaluation, disclosure, and marketing.

  Source
• 1991Kelco air-emissions pollutionControversy

  Merck subsidiary Kelco was linked to volatile-organic-compound emissions in the San Diego area. Merck later paid an environmental penalty and installed equipment intended to reduce emissions.

  Source
• 1933Merck’s activities during the Nazi period and wartime forced laborControversy

  Historical accounts describe the political roles of company leader Karl Emanuel Merck during Nazi rule, the production of war-related chemicals and pharmaceuticals, and the use of forced laborers at the Darmstadt plant during the Second World War.

  Source

• 2026Merck KGaA agrees to acquire Bio-Techne

  Merck KGaA announced an agreement to acquire Bio-Techne, describing the transaction as a way to expand its life-science tools, multi-omics, analytical-technology, bioprocessing, and advanced-therapeutics capabilities.

  M&A
  Source
• 2025Merck KGaA concludes the SpringWorks acquisition

  Merck KGaA completed its acquisition of SpringWorks Therapeutics, adding a rare-tumor medicines portfolio and expanding its healthcare business.

  M&A
  Source
• 2024Merck faces continuing trademark-name confusion with Merck & Co.

  Media coverage continued to note confusion between the German Merck Group and the separately owned U.S. company Merck & Co.

  LawsuitOther
  Source
• 2021Merck invests in semiconductor supply-chain joint venture

  Merck announced a planned investment with Palantir Technologies focused on digital and supply-chain challenges affecting semiconductor operations.

  Other
  Source
• 2021Merck withdraws investigational COVID-19 vaccine program

  Merck discontinued development of its V590 and V591 COVID-19 vaccine candidates after early clinical results did not support continued development.

  Other
  Source
• 2019Merck completes acquisition of Versum Materials

  Merck completed its purchase of Versum Materials to strengthen electronic materials and semiconductor-related offerings.

  M&A
  Source
• 2019Merck acquires Antelliq Group

  Merck Animal Health acquired Antelliq, adding animal-identification, monitoring, and data technologies to its veterinary-health business.

  M&A
  Source
• 2017Merck acquires AstraZeneca’s Lynparza rights

  Merck entered an agreement with AstraZeneca concerning Lynparza, a PARP inhibitor used in oncology, broadening its cancer-treatment portfolio.

  M&AProduct launch
  Source
• 2015Merck completes Sigma-Aldrich acquisition

  The transaction was completed and became a major foundation of Merck’s Life Science business.

  M&A
  Source
• 2015Merck acquires Cubist Pharmaceuticals

  Merck acquired Cubist for approximately $9.5 billion, strengthening its hospital and acute-care anti-infective portfolio.

  M&A
  Source
• 2014Merck announces acquisition of Sigma-Aldrich

  Merck announced an agreement to acquire Sigma-Aldrich, creating a much larger global life-science supplier.

  M&A
  Source
• 2014FDA approves pembrolizumab for melanoma

  The FDA approved pembrolizumab, later marketed as Keytruda, for advanced melanoma under the breakthrough-therapy framework.

  Product launchProduct generation
  Source
• 2014Merck acquires Idenix Pharmaceuticals

  The company acquired Idenix for approximately $3.85 billion, obtaining hepatitis C antiviral research assets.

  M&A
  Source
• 2013Merck announces major workforce reduction

  The company announced additional job reductions as part of a cost-reduction program intended to simplify operations and reduce expenses.

  Other
  Source
• 2010Merck completes acquisition of Millipore

  Merck acquired Millipore Corporation, substantially expanding its laboratory and biopharmaceutical process technology business.

  M&A
  Source
• 2009Merck completes Schering-Plough merger

  Merck completed its approximately $41 billion combination with Schering-Plough, substantially expanding its pharmaceutical, vaccine, and consumer-health businesses.

  M&A
  Source

1. Merck KGaA, Darmstadt, Germany, agrees to acquire Bio-Techne
2. Merck concludes SpringWorks acquisition
3. 英国涉及默克公司的商标裁决
4. 与德国默克集团的商标纠纷